Health & Biotech
Stories by Tim Boreham
Health & Biotech
Alive and Kicking: Noxopharm has difficult brain cancer in its sights
Health & Biotech
Dr Boreham’s Crucible: Diverse ASX biotech gun Telix brushes off suggestions it’s peaked
Experts
CRITERION: Opportunity knocks for some amid crackdown on NDIS fraud
Health & Biotech
Health Kick Podcast: Creating hope for debilitating diseases
Experts
CRITERION: Do these ASX stocks have the REIT stuff for investors?
Experts
Dr Boreham’s Crucible: Can this Aussie medtech rise as it lifts a cumbersome NHS into the digital age?
Experts
CRITERION: Reporting season shows the good, the bad and the ugly on the ASX
Experts
CRITERION: Where can ASX investors turn for ‘inexpensive defensives’ in the event of recession?
Experts
Dr Boreham’s Crucible: In the Alzheimer’s treatment Olympics, this Aussie biotech is a chance of gold
Experts
CRITERION: Faster, higher, stronger? ASX sports plays going for market-cap gold
Experts